Combined modality therapy for limited-disease Small Cell Lung Cancer

Luis Raez, Michael Samuels, Rogerio Lilenbaum

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Small Cell lung Cancer (SCLC) is highly sensitive to chemotherapy and radiotherapy. However, despite initial responses, relapses are common and most patients eventually succumb to this disease. Patients with limited-disease SCLC represent approximately 30% of all patients with SCLC, and are potentially curable when treated with combined chemotherapy and thoracic radiotherapy (TRT). Chemotherapy consists of four cycles of the combination of cisplatin and etoposide (PE). Thoracic radiotherapy should be started with the first or second cycle of chemotherapy, and preferably administered twice daily for 3 weeks. Prophylactic cranial irradiation (PCI) is recommended for patients who achieve a complete response. Surgery is of limited value in SCLC, except in patients who present with a solitary pulmonary nodule. Approximately 20% to 25% of patients with limited disease (LD)-SCLC can be cured with this aggressive approach. Newer treatment modalities are currently under investigation.

Original languageEnglish (US)
Pages (from-to)69-74
Number of pages6
JournalCurrent Treatment Options in Oncology
Volume6
Issue number1
DOIs
StatePublished - Jan 2005
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Combined modality therapy for limited-disease Small Cell Lung Cancer'. Together they form a unique fingerprint.

  • Cite this